These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 16624482)

  • 21. Immunohistochemical expression of Ki-67, Cyclin D1, p16INK4a, and Survivin as a predictive tool for recurrence and progression-free survival in papillary urothelial bladder cancer pTa / pT1 G2 (WHO 1973).
    March-Villalba JA; Ramos-Soler D; Soriano-Sarrió P; Hervás-Marín D; Martínez-García L; Martínez-Jabaloyas JM
    Urol Oncol; 2019 Feb; 37(2):158-165. PubMed ID: 30446453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclin D1 expression in papillary superficial bladder cancer: its association with other cell cycle-associated proteins, cell proliferation and clinical outcome.
    Sgambato A; Migaldi M; Faraglia B; De Aloysio G; Ferrari P; Ardito R; De Gaetani C; Capelli G; Cittadini A; Trentini GP
    Int J Cancer; 2002 Feb; 97(5):671-8. PubMed ID: 11807796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of pRb, p53, p16 and cyclin D1 and their clinical implications in urothelial carcinoma.
    Lee K; Jung ES; Choi YJ; Lee KY; Lee A
    J Korean Med Sci; 2010 Oct; 25(10):1449-55. PubMed ID: 20890425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of p14ARF, p15INK4b, and p16INK4a inactivation in malignant peripheral nerve sheath tumors.
    Endo M; Kobayashi C; Setsu N; Takahashi Y; Kohashi K; Yamamoto H; Tamiya S; Matsuda S; Iwamoto Y; Tsuneyoshi M; Oda Y
    Clin Cancer Res; 2011 Jun; 17(11):3771-82. PubMed ID: 21262917
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters.
    Lopez-Beltran A; Luque RJ; Alvarez-Kindelan J; Quintero A; Merlo F; Requena MJ; Montironi R
    Am J Clin Pathol; 2004 Sep; 122(3):444-52. PubMed ID: 15362377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis.
    Oda Y; Yamamoto H; Takahira T; Kobayashi C; Kawaguchi K; Tateishi N; Nozuka Y; Tamiya S; Tanaka K; Matsuda S; Yokoyama R; Iwamoto Y; Tsuneyoshi M
    J Pathol; 2005 Dec; 207(4):410-21. PubMed ID: 16177957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p53, p16 and cyclin D1: molecular determinants of radiotherapy treatment response in oral carcinoma.
    Jayasurya R; Francis G; Kannan S; Lekshminarayanan K; Nalinakumari KR; Abraham T; Abraham EK; Nair MK
    Int J Cancer; 2004 May; 109(5):710-6. PubMed ID: 14999779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors.
    Eymin B; Gazzeri S; Brambilla C; Brambilla E
    Oncogene; 2002 Apr; 21(17):2750-61. PubMed ID: 11965548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mcm2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK20, Ki67 and histological grade.
    Burger M; Denzinger S; Hartmann A; Wieland WF; Stoehr R; Obermann EC
    Br J Cancer; 2007 Jun; 96(11):1711-5. PubMed ID: 17505513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers.
    Sarkar S; Jülicher KP; Burger MS; Della Valle V; Larsen CJ; Yeager TR; Grossman TB; Nickells RW; Protzel C; Jarrard DF; Reznikoff CA
    Cancer Res; 2000 Jul; 60(14):3862-71. PubMed ID: 10919661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of cell-cycle-regulated proteins pRb2/p130, p107, p27(kip1), p53, mdm-2, and Ki-67 (MIB-1) in prostatic gland adenocarcinoma.
    Claudio PP; Zamparelli A; Garcia FU; Claudio L; Ammirati G; Farina A; Bovicelli A; Russo G; Giordano GG; McGinnis DE; Giordano A; Cardi G
    Clin Cancer Res; 2002 Jun; 8(6):1808-15. PubMed ID: 12060621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical expression of the p53, mdm2, p21/Waf-1, Rb, p16, Ki67, cyclin D1, cyclin A and cyclin B1 proteins and apoptotic index in T-cell lymphomas.
    Kanavaros P; Bai M; Stefanaki K; Poussias G; Rontogianni D; Zioga E; Gorgoulis V; Agnantis NJ
    Histol Histopathol; 2001 Apr; 16(2):377-86. PubMed ID: 11332692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alterations of cell cycle regulators are less frequent in advanced non-small cell lung cancer than in resectable tumours.
    Gugger M; Kappeler A; Vonlanthen S; Altermatt HJ; Ris HB; Lardinois D; Borner MM; Heighway J; Betticher DC
    Lung Cancer; 2001; 33(2-3):229-39. PubMed ID: 11551418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
    Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
    J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cell cycle regulators in bladder cancer: relationship to schistosomiasis.
    Eissa S; Ahmed MI; Said H; Zaghlool A; El-Ahmady O
    IUBMB Life; 2004 Sep; 56(9):557-64. PubMed ID: 15590562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification.
    Santos L; Amaro T; Costa C; Pereira S; Bento MJ; Lopes P; Oliveira J; Criado B; Lopes C
    Int J Cancer; 2003 Jun; 105(2):267-72. PubMed ID: 12673690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma.
    Theodoropoulos VE; Lazaris AC; Kastriotis I; Spiliadi C; Theodoropoulos GE; Tsoukala V; Patsouris E; Sofras F
    BJU Int; 2005 Feb; 95(3):425-31. PubMed ID: 15679808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression and prognostic implications of cell cycle regulatory molecules, p16, p21, p27, p14 and p53 in germinal centre and non-germinal centre B-like diffuse large B-cell lymphomas.
    Paik JH; Jeon YK; Park SS; Kim YA; Kim JE; Huh J; Lee SS; Kim WH; Kim CW
    Histopathology; 2005 Sep; 47(3):281-91. PubMed ID: 16115229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apoptosis, proliferation and p53, cyclin D1, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder.
    Moonen L; Ong F; Gallee M; Verheij M; Horenblas S; Hart AA; Bartelink H
    Int J Radiat Oncol Biol Phys; 2001 Apr; 49(5):1305-10. PubMed ID: 11286838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
    Tzai TS; Tsai YS; Chow NH
    Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.